Stem Cell Institute and Medistem Panama founder, Neil Riordan, PhD discusses clinical trials for multiple sclerosis and rheumatoid arthritis using umbilical cord tissue-derived mesenchymal stem cells at our fall stem cell seminar in San Antonio.
For more information about these trials and others, please visit www.translationalbiosciences.com. The multiple sclerosis trial is full but the RA trial is still recruiting as of November 24, 2014.
How do we select umbilical cords for use? Medistem has identified proteins and genes in the cells that allow us to screen hundreds of umbilical cords to select only the ones containing the specific types of cells that have the best anti-inflammatory properties, the best immune modulating capacity and the best ability to stimulate regeneration.
How therapy using umbilical cord tissue-derived mesenchymal stem cells (MSCs) differs from bone marrow transplants used in cancer patients.
Properties of umbilical cord MSCs:
- Modulate the immune system
- Increase the number of T-regulatory cells
- Block clonal expansion of activated T cells
- MSCs in patients with autoimmune diseases don’t work properly
How demyelination occurs in MS patients and how MSCs act on the immune system to slow it down or stop it.
Treated MS patient follow-up survey results at 120 days and 1 year after treatment.
Television news story about Sam Harrell’s return to coaching football after severe MS symptoms forced him into early retirement.
Results from a 172 patient study on treating rheumatoid arthritis with intravenous umbilical cord tissue mesenchymal stem cells in which all patients improved.
These trials may be viewed on the National Institutes of Health web site www.clinicaltrials.gov
Those interested in stem cell therapy for MS may still apply for private treatment on this site.